Lexicon Stock Halted Thursday Pending FDA Meeting
17 Gennaio 2019 - 1:45PM
Dow Jones News
By Chris Wack
Lexicon Pharmaceuticals Inc. (LXRX) said NASDAQ has halted
trading of the company's common stock because the U.S. Food and
Drug Administration's Endocrinologic and Metabolic Drugs Advisory
Committee is meeting Thursday to review Lexicon collaborator
Sanofi's New Drug Application for sotagliflozin, an investigational
oral treatment for adults with type 1 diabetes.
The biopharmaceutical company said the Prescription Drug User
Fee Act date for completion of the review of the New Drug
Application for sotagliflozin is anticipated to be March 22,
2019.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 17, 2019 07:30 ET (12:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Apr 2023 a Apr 2024